Developing new treatments for rare and orphan neurological conditions.
Location: United States, Illinois, Chicago
Total raised: $285M
Investors 3
Date | Name | Website |
18.07.2021 | Valor Equi... | valorep.co... |
- | Horizon Te... | horizontec... |
16.11.2022 | Bain Capit... | baincapita... |
Funding Rounds 2
Date | Series | Amount | Investors |
04.11.2022 | Series D | $250M | - |
23.03.2021 | Series C | $35M | - |
Mentions in press and media 12
Date | Title | Description | Source |
03.01.2023 | This biotech founder has a new plan to treat Tourette Syndro... | Jeff Aronin, CEO of Paragon Biosciences and founder of Emalex Biosciences. Paragon Biosciences Emal... | businessin... |
04.11.2022 | Emalex Biosciences Raises $250M in Series D Financing Round | Emalex Biosciences, a Chicago, IL-based biotechnology company, raised $250M in Series D funding. Th... | finsmes.co... |
03.11.2022 | Bain Capital-Backed Emalex Bio Lands $250M for Pivotal Test ... | Tourette syndrome causes involuntary muscle and vocal tics that can be treated with several drugs, b... | medcitynew... |
03.11.2022 | Emalex Biosciences Announces $250M Series D | CHICAGO, IL, Emalex Biosciences announced the closing of an upsized and oversubscribed $250 millio... | vcnewsdail... |
03.11.2022 | Emalex Raises $250M For Tourette Syndrome Treatment | 4 Shares Email Facebook Twitter LinkedIn Not all late-stage companies are feeling the funding droug... | news.crunc... |
23.03.2021 | Emalex Biosciences Raises $35M in Series C Funding | Emalex Biosciences, Inc., a Chicago, IL-based biopharmaceutical company founded to develop treatment... | finsmes.co... |
23.03.2021 | Emalex Biosciences Raises $35 Million in Series C Preferred ... | CHICAGO, March 23, 2021 /PRNewswire/ -- Emalex Biosciences, Inc. ("Emalex"), a biopharma... | prnewswire... |
23.03.2021 | Emalex Biosciences Scoops Up $35M Series C | CHICAGO, IL, Emalex Biosciences today announced $35 million in Series C Preferred Stock funding. ... | vcnewsdail... |
23.03.2021 | Jeff Aronin's Emalex raises $35M Series C; British prote... | Jeff Aronin has a new raise in place for one of his portfolio companies. Emalex Biosciences is... | endpts.com... |
- | Emalex Biosciences, Inc. | “Developing new treatments for rare and orphan neurological conditions.” | fastfounde... |
Show more